Search
gepotidacin (Blujepa)
Indications:
- treatment of uncomplicated urinary tract infections* [1] (UTIs)
- treatment of uncomplicated urogenital gonorrhea# [2]
* non-inferior to nitrofurantoin for treatment of uncomplicated UTIs
* FDA-approved March 2025
# non-inferior to ceftriaxone plus azithromycin for urogenital N gonorrhoeae [2]
Dosage:
- 1500 mg PO BID for 5 days (UTI)
- two 3000 mg PO doses administered 10-12 h apart gonorrhea [2]
Adverse effects:
- diarrhea (14%)
Antimicrobial activity:
- common uropathogens, including clinically important drug-resistant organisms
Mechanism of action:
- inhibits bacterial DNA replication
- inhibition of two type II topoisomerase enzymes
General
other antibiotic
Database Correlations
PUBCHEM correlations
References
- Wagenlehner F, Perry CR, Hooton TM et al
Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract
infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-
dummy, phase 3, non-inferiority trials.
Lancet. 2024 Feb 8:S0140-6736(23)02196-7.
PMID: 38342126
- Wagenlehner F, Perry CR, Hooton TM et al et al.
Plain language summary: Efficacy and safety of gepotidacin, a new oral antibiotic,
compared with nitrofurantoin, a commonly used oral antibiotic, for treating
uncomplicated urinary tract infection.
Future Microbiol 2025 Mar; 20:265-275
PMID: 39988828 PMCID: PMC11951693
https://www.tandfonline.com/doi/abs/10.1080/17460913.2025.2460387
- Ross JDC, Wilson J, Workowski KA et al
Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1):
a phase 3 randomised, open-label, non-inferiority, multicentre study.
Lancet. 2025 Apr 11:S0140-6736(25)00628-2
PMID: 40245902
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00628-2/abstract